Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
81. |
ECCT/25/02/03 | NOZE20240219TB “Validation of a Digital Olfaction Based Breathalyzer Device for Non-Invasive Detection of Volatile Biomarkers in Patients with and without Tuberculosis: Case Control Study”. |
Principal Investigator(s) 1. Ibrahim Daud Site(s) in Kenya KEMRI/WRP CRC Kericho |
15-05-2025 |
View |
82. |
ECCT/25/02/02 | HPV vaccine feasibility study Generating local data on HPV vaccination impact and training needs at the level of vaccine implementers – A feasibility study |
Principal Investigator(s) 1. Prof Kenneth Ngure Site(s) in Kenya KEMRI-CCR PHRD( (THIKA) PROJECT |
29-04-2025 |
View |
83. |
ECCT/25/02/01 | IMPAACT 2037 Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 |
Principal Investigator(s) 1. Lucy C. Koech Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project |
18-12-2025 |
View |
84. |
ECCT/25/01/03 | FETAL LITE STUDY Evaluation of Fetal Lite Device for Reducing Perinatal Mortality through Enhanced Labor Monitoring in Low-Resource Settings: A Pilot Study at Kenyatta National Hospital |
Principal Investigator(s) 1. GEORGE GWAKO 2. Alfred Osoti 3. Rosa Chemwey Site(s) in Kenya Kenyatta National Hospital |
13-05-2025 |
View |
85. |
ECCT/25/01/01 | FLORAL An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study. |
Principal Investigator(s) 1. Bernhard Ogutu Site(s) in Kenya 1. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county) 2. Gertrude’s Children’s Hospital (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 5. KEMRI WALTER REED KERICHO (Kericho county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) |
24-04-2025 |
View |
86. |
ECCT/24/12/03 | PrEMIA Implementation study Multi-product PrEP delivery to young women seeking reproductive health services and coverage of HIV prevention |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD( (THIKA) PROJECT |
04-05-2025 |
View |
87. |
ECCT/24/12/02 | IAVI C113 IAVI C113: A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in interferon gamma release assay positive adolescents and adults aged 14-45 years, living in a TB endemic region. |
Principal Investigator(s) 1. Videlis Nduba 2. Tina Lucas Site(s) in Kenya 1. KEMRI,Centre for Respiratory Diseases Research (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
21-05-2025 |
View |
88. |
ECCT/24/12/01 | PDMC-Saves Lives (PDMC-SL) Delivery strategies for malaria chemoprevention in the post-discharge management of hospitalised children with severe anaemia or severe malaria: cluster and individually randomised controlled implementation trials with nested economic evaluation in Kenya and Benin |
Principal Investigator(s) 1. Juliet Otieno Awori 2. Simon Kariuki Site(s) in Kenya Health facilities with blood transfusion services in malaria-endemic areas in Western Kenya |
16-04-2025 |
View |
89. |
ECCT/24/11/03 | REALISE STUDY PROTOCOL A Pragmatic Phase III Multi-Centre Clinical Trial to Evaluate the Safety and 1 Effectiveness of a Single Dose of an Albendazole-Ivermectin Coformulation vs 2 Albendazole for Preventive Chemotherapy of Soil-Transmitted Helminth Infections in 3 School-Aged Children |
Principal Investigator(s) 1. Alejandro Javier Krolewiecki Site(s) in Kenya Kwale county |
19-06-2025 |
View |
90. |
ECCT/24/11/01 | Sparkle A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Site 1401:Victoria Biomedical Research Institute (Kisumu county) 2. Site 1402:Ahero Clinical trials Unit (Kisumu county) 3. Site 1403:International Cancer institute (Uasin Gishu county) 4. Site 1404:Kondele Childrens Hospital (Kisumu county) 5. Site 1405:KEMRI/CRDR KEMRI Clinical Research Annex (Kisumu county) 6. Site 1406:Gertrudes Children’s Hospital (Nairobi City county) |
13-05-2025 |
View |